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Abstract
Influenza A virus (IAV) infection poses a serious health threat and novel antiviral strategies
are needed. Defective interfering particles (DIPs) can be generated in IAV infected cells due
to errors of the viral polymerase and may suppress spread of wild type (wt) virus. The antivi-
ral activity of DIPs is exerted by a DI genomic RNA segment that usually contains a large
deletion and suppresses amplification of wt segments, potentially by competing for cellular
and viral resources. DI-244 is a naturally occurring prototypic segment 1-derived DI RNA in
which most of the PB2 open reading frame has been deleted and which is currently devel-
oped for antiviral therapy. At present, coinfection with wt virus is required for production of
DI-244 particles which raises concerns regarding biosafety and may complicate interpreta-
tion of research results. Here, we show that cocultures of 293T and MDCK cell lines stably
expressing codon optimized PB2 allow production of DI-244 particles solely from plasmids
and in the absence of helper virus. Moreover, we demonstrate that infectivity of these parti-
cles can be quantified using MDCK-PB2 cells. Finally, we report that the DI-244 particles
produced in this novel system exert potent antiviral activity against H1N1 and H3N2 IAV but
not against the unrelated vesicular stomatitis virus. This is the first report of DIP production
in the absence of infectious IAV and may spur efforts to develop DIPs for antiviral therapy.
Introduction
Influenza A virus infection is responsible for annual influenza epidemics and intermittent pan-
demics that are associated with significant morbidity and mortality [1]. The ability of IAV to
constantly change in response to immune pressure or antiviral treatment limits the effective-
ness of currently used antiviral interventions. Thus, vaccines against seasonal influenza need
to be annually reformulated and will provide little if any protection against pandemic influenza
[1]. Moreover, the effectiveness of antivirals targeting the viral proteins M2 and neuraminidase
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is compromised by the frequent emergence and transmission of resistance mutations [1, 2].
Therefore, novel approaches to combat influenza are urgently needed.
IAVs are enveloped and harbor eight segments of genomic viral RNA. Defective interfering
(DI) genomic segments can be generated in IAV infected cells due to errors of the viral poly-
merase [3, 4]. DI segments usually harbor a large deletion which inactivates the open reading
frame encoded by the segment [3, 4]. The DI segments can interfere with amplification of wild
type (wt) segments, potentially by competing for viral and cellular resources required for seg-
ment replication. Moreover, DI RNAs can be packaged into progeny virions, termed defective
interfering particles (DIPs), and coinfection of target cells with DIPs and IAV will result in
preferential amplification of DIPs and suppression of IAV spread [3, 4]. This effect has been
observed in cell culture [5–8] and in experimentally infected animals [5, 9–15] and may extend
to unrelated viruses [14, 16], due to the activation of the interferon system [15, 16]. Moreover,
DIP application in a therapeutic or preventive setting prevents or ameliorates influenza in ani-
mal models [3–5, 10–16]. In sum, DIPs can be considered natural antivirals produced in the
context of infection with IAV and many other viruses and may provide a basis for the develop-
ment of new strategies for antiviral intervention.
At present, amplification of DIPs requires coinfection of cells with DIPs and wt virus,
termed standard or helper virus, which subsequently needs to be inactivated by UV light [3, 4,
17, 18]. The presence of standard virus poses a safety concern when products for animal and
human use are generated and complicates the interpretation of experimental data. Plasmid sys-
tems encoding for wt and DI segments along with cell lines expressing the IAV proteins for
which the genomic information has been lost upon DI RNA formation might circumvent this
issue [4, 19]. However, expression of the viral polymerase subunit PB2 in trans was found to be
insufficient for robust amplification of IAV variants harboring temperature sensitive muta-
tions [20, 21] and it has been speculated that similar limitations might apply to the production
of DIPs [4]. Moreover, it has been suggested that PB2 expression might be toxic to cells [4].
Therefore, it is currently unknown whether the strategy outlined above might allow for pro-
duction of segment 1-derived DIPs and at present no system for generation of DIPs in the
absence of standard virus has been reported.
DI-244 is a naturally occurring DI-RNA found in hen’s eggs [22]. DI-244 is derived from
segment 1, which encodes PB2, and harbors a 1,946 nucleotides comprising deletion [4, 22].
This deletion removes most of the PB2 ORF but leaves the 3’ 244 nucleotides and 5’ 151 nucle-
otides of segment 1 intact which are sufficient for segment replication and packaging [4, 22].
Here, we investigated whether coexpression of wt segments 2–8, PB2 protein and DI-244 RNA
allows for production of DIPs. Employing a novel DI-244 variant encoding mScarlet-i, we
show that DI-244-based DIPs are efficiently produced in cells expressing a codon optimized
version of PB2 and that these DIPs exert potent antiviral activity.
Material and methods
Plasmids and oligonucleotides
Plasmids for rescue of the A/PR/8/34 (H1N1) strain, pHW191-pHW198, were used through-
out this study and have been previously described [23]. To generate a retroviral vector encod-
ing PB2, the PB2 open reading frame was amplified from pHW191 using primers PB2-QCX
IP-5N (5- CCGCGGCCGCACCATGGAAAGAATAAAAGAACTAC-3) and PB2-3XBgl (5-GG
AGATCTCGAGCTAATTGATGGCCATCCGAAT-3) and cloned into the retroviral vector
pQCXIP-mcs using NotI and XhoI [24]. This self-inactivating vector allows constitutive
expression of PB2 and puromycin resistance genes coupled by an internal ribosome entry site
(IRES). An optimized sequence of PB2 was generated by hand to maximize sequence deviation
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from PB2 and optimizing codon usage for influenza A virus and humans (S1 Fig). This
sequence was synthesized and cloned by GeneArt (Regensburg, Germany) and subcloned
using NotI and XhoI sites into pQCXIP-mcs. A plasmid for DI-244 rescue was generated by




TAACTGAGGGGATTCCTCATT-3)/fluA AarI-PB1-2341R (5- CGATCACCTGC TCTCTAT
TAGTAGAAACAAGGCATTT-3). The product of the splice overlap PCR was then purified and
amplified with the segment specific primer pair fluA AarI-PB2-1G/fluA AarI-PB1-2341R and
cloned into pHW2000-GGAarI, using golden gate cloning, generating pHW2000-DI244-mcs
[25]. In addition, a construct containing a multiple cloning site (mcs) was generated for later
insertion of reporter genes. For this, the PCR fragments were amplified using pHW191 as tem-
plate and primer pairs fluA AarI-PB2-1G/IAVseg1-DI244rep-rev (5- AATGAGGAATCCCCT
CAGTTAAGCGGCCGCTGCGGTACCAGATCTCTTCTCCTGTCTTCC TGA-3) and IAVseg1-
DI244rep-for (5- TCAGGAAGACAGGAGAAGAGATCTGGTACCGCA GCGGCCGCTTAACTG
AGGGGATTCCTCATT-3)/ fluA AarI-PB1-2341R followed by splice overlap joining and
golden gate cloning. As reporter gene, mScarlet-i without internal SalI and NotI sites and
fused to the porcine teschovirus-1 (PTV1) 2A sequence (GATNFSLLKQAGDVEENPGP) was
cloned into the mcs as a BglII/NotI fragment. In this way, a PB2 (aa 1–41)-2A-mScarlet-i ORF
was generated, which allows the detection of the presence of DI-244 via mScarlet-i fluores-
cence. The template for mScarlet-i, pmScarlet-i_C1, was a gift from Dorus Gadella (Addgene
plasmid # 85044) [26]. The integrity of PCR-amplified, cloned sequences was verified by
sequence analysis.
Cells and viruses
All cells were cultured at 37˚C and 5% CO2. 293T human embryonic kidney cells and Vero
cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) containing 10%
fetal bovine serum (FBS, Gibco), penicillin (Pen, 100 IU/ml) and streptomycin (Strep, 100 μg/
ml). 293T cell lines stably expressing PB2 were grown in the presence of 1 μg/ml puromycin.
Madin-Darby canine kidney cells (MDCK) were cultured in Glasgow’s MEM (GMEM) with
10% fetal bovine serum (FBS, Gibco) and Pen/Strep. All cell lines were obtained from collabo-
rators and were regularly checked for mycoplasma contamination. MDCK cells stably express-
ing PB2 or PB2opt were cultivated in the presence of 1.5 μg/ml puromycin. Influenza A viruses
A/Panama/2007/99 (H3N2) [24] and A/PR/8/34 (H1N1) produced in embryonated chicken
eggs were used to assess the antiviral activity of DIPs. We further employed a recombinant
vesicular stomatitis virus (VSV) that expresses a dual reporter consisting of eGFP and firefly
luciferase from an additional transcription unit located between the open reading frames for
the viral glycoprotein and polymerase [27].
Production of retroviral vectors
The production of MLV particles for transduction of cells followed an established protocol
[25, 28]. Briefly, 293T cells seeded in T25 flasks were transfected with 6 μg of retroviral vector
(e.g. pQCXIP-PB2), 3 μg MLV-gag-pol plasmid and 3 μg VSV-G expression plasmid, employ-
ing the calcium phosphate transfection method. The culture medium was exchanged at 8 h
after transfection. After 48 h, MLV particle-containing supernatant was harvested, cleared by
passing through a 0.45 μm filter, aliquoted and then stored at -80˚C.
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Transduction and selection of cell lines
For retroviral transduction, cells were seeded in 96-well plates at 5,000 (MDCK) or 10,000
(293T) cells/well in 50 μl cell culture medium. On the next day, 50 μl of supernatant containing
MLV particles was added per well followed by spinoculation at 4,000 × g for 30 min for
enhancement of transduction [29]. Two days after transduction, the cells were detached and
transferred into 24-well plates containing cell culture medium supplemented with 1 μg/ml
(293T) and 1.5 μg/ml (MDCK) puromycin. In parallel, non-transduced cells were treated simi-
larly to control for effective cell killing by the antibiotics.
Mini-replicon assay
293T were seeded at a cell density of 2 × 105 cells/well in 12-well plates. The following day, the
cells were transfected using the calcium phosphate method. The concentrations of plasmids to
be transfected were largely adapted from published work [30]: 10 ng of pCAGGS plasmids
encoding viral RNA polymerase proteins (PB2, PB, PA) and 100 ng of plasmid encoding NP
were cotransfected with 50 ng of plasmid pPolI-Luc, which encodes the firefly luciferase
reporter gene flanked by the noncoding regions of segment 8 of A/WSN/33. Empty plasmid
was used to ensure that all transfections were conducted with the same total amount of plas-
mid DNA. For analysis of functionality of PB2 in 293T cells stably expressing this protein,
transfection was carried out as described above but the plasmid encoding PB2 was omitted. As
control, the plasmid encoding PB1 was omitted. The cells were washed at 6–8 h after transfec-
tion and harvested at 24 h post transfection. Luciferase activities in cell lysates were measured
using the Plate Chameleon V plate reader (Hidex) and Microwin 2000 software.
Immunoblot
For analysis of PB2 expression in 293T and MDCK cells, the cells were seeded in 6-well plates,
incubated for 24 h, harvested and lysed in 200 μL of Laemmli SDS-PAGE sample buffer (5% glyc-
erine, 1% SDS, 2.5% ß-mercaptoethanol, 0.5% Bromophenol blue, 0.5 mM EDTA,0.5M Tris pH
6.8). Samples were heated to 95˚C for 10 min and separated via SDS-PAGE using 12.5% poly-
acrylamide gels. Proteins were then transferred onto a nitrocellulose membrane (GE health care)
using a Mini-PROTEAN Tetra Cell (BioRad) powered at 110 V for 90 minutes. Membranes were
blocked with 5% skimmed milk diluted in PBS-Tween and incubated with primary rabbit poly-
clonal antibodies against PB2 (1:1,000, GenTex, Irvine, USA) overnight at 4˚C. Subsequently,
membranes were washed and incubated with anti-rabbit HRP (horseradish peroxidase)-conju-
gated secondary antibodies (1:10,000, Dianova) for one hour. Finally, chemiluminescent sub-
strate HRP juice plus (P.J.K.) was added onto the membrane and bands were visualized using a
ChemoCam imager (INTAS). In order to detect ß-actin, the membrane was subsequently
stripped using stripping buffer (62.5 mM Tris HCl pH 6.8, 2% SDS, 100 mM ß-mercaptoethanol)
for 30 min at 5˚C, washed three times with PBS-Tween, and incubated with anti ß-actin mouse
(1:500 Sigma-Aldrich) overnight. The membrane was then washed and incubated with anti-
mouse HRP-conjugated secondary antibody (1:10,000, Dianova) for one hour. HRP juice plus
was added and bands were visualized as previously described. Quantification of PB2 and PB2opt
expression was carried out using the program ImageJ (FIJI distribution) [31]. In order to normal-
ize data, signals measured for PB2/PB2opt were divided by those measured for beta-actin.
Production of defective interfering particles
For DIP production, a coculture of 200,000 MDCK cells and 700,000 293T cells stably express-
ing PB2 was seeded in T25 flasks. The next day, cells were cotransfected via the calcium
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phosphate method with 1 μg each of plasmids encoding DI-244-mScarlet-i and wt IAV genomic
segments 2–8. Culture medium was changed at 8 h post transfection. At 48 h post transfection,
cells were washed with phosphate buffered saline (PBS) without calcium and magnesium and
DMEM medium supplemented with 0.2% BSA (MACS BSA), 0.5 μg/ml tosyl-phenylalany-
chloromethyl-ketone (TPCK)-trypsin (Sigma), penicillin (100 IU/ml) and streptomycin (100 μg/
ml) was added. As negative control, transfection of parental MDCK and 293T cells was analyzed.
Supernatants were harvested from all cultures at 4, 6, 8 and 10 days post transfection, cleared by
centrifugation at 4,000 rpm for 10 min to remove debris, aliquoted and stored at -80˚C. Infectiv-
ity of supernatants was analyzed by focus formation assay as described [25, 32] but using MDCK
cells expressing PB2 or PB2opt as targets. In brief, MDCK-PB2/PB2opt cells seeded in 96-well
plates were washed and incubated for 1 h with serial dilutions of DIP-containing supernatants.
Thereafter, supernatants were removed and infection medium (GMEM with 0.2% BSA and Pen/
Strep) supplemented with 0.5% methylcellulose and 0.5 μg/ml TPCK-trypsin was added. Plates
were incubated for 72 h and then stained using anti IAV polyclonal antibody (Millipore).
Immunofluorescence
Images were taken on a Zeiss LSM800 equipped with a 10x/0.45 plan-apochromat objective,
488 nm and 561 nm diode lasers and ZEN imaging software (Zeiss). Fluorescent signals (red
channel, 561 nm laser) were detected with GaAsP detector employing the same sensitivity for
all images of a series, while bright field signals were recorded with an ESID detector (photodi-
ode) with individually adjusted sensitivity.
Analysis of antiviral activity of DIPs
To test antiviral activity of DIPs against IAV and unrelated VSV, we performed infection experi-
ments in the presence of DIP-containing or DIP-free supernatants and subsequently compared
viral titers in the culture supernatants. For this, MDCK cells were seeded in 96-well plates at a den-
sity of 10,000 cells/well. On the next day, DIP-containing supernatants or DIP-free control superna-
tants were 10-fold serially diluted. Subsequently, MDCK cells were washed twice with PBS and
50 μl of the respective supernatants were mixed with 50 μl of virus and the mixture inoculated onto
the MDCK cells. After a 1 h incubation, 100 μl of fresh infection medium supplemented with
0.5 μg/ml TPCK-trypsin was added and the cells were further incubated for 24 h (VSV) or 72 h
(IAV) before viral titers in the culture supernatants were determined. Virus titration was performed
on confluent monolayers of MDCK (IAV) or Vero (VSV) cells that were grown in 96-well plates.
After aspiration of the culture medium, cells were washed twice with PBS and inoculated with 50 μl
of 10-fold serial dilutions of the culture supernatants of IAV or VSV infected MDCK cells. After 1 h
of incubation with IAV containing supernatants, the medium was removed and 100 μl infection
medium supplemented with 1% Avicel and 0.5 μg/ml TPCK-trypsin (IAV/MDCK) was added per
well. After 1h incubation with VSV-containing supernatants, 200 μl infection medium supple-
mented with 0.5% methylcellulose (VSV/Vero) were added on top, and the cells were further incu-
bated for 24 h. IAV titers were quantified by antibody staining, using the focus formation assay as
previously described [25, 32]. In order to quantify VSV titers, eGFP-positive foci were counted
under the fluorescence microscope. All titers are given as focus forming units per ml (ffu/ml).
Results
Generation of 293T and MDCK cells stably expressing functional PB2
We sought to determine whether DI-244 particles can be amplified in the absence of standard
virus if producer cells are engineered to express PB2. For this, we first used retroviral
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transduction and selection antibiotics to generate 293T and MDCK cell lines stably expressing
PB2. Immunoblot revealed that the cell lines obtained by selection expressed robust levels of
PB2 (Fig 1A and Fig 1B). In order to analyze whether PB2 is functional in these cells, we
employed a mini-replicon system, which measures the amplification of a firefly luciferase
encoding IAV reporter segment upon coexpression of PB2, PB1, PA and NP [30]. We found
that transfection of 293T-PB2 cells with a plasmid encoding the reporter segment alone yielded
luciferase activity in the background range while cotransfection of PB2, PB1, PA and NP
expression plasmids increased luciferase activity more than 1,000-fold (Fig 1C). Importantly,
this increase was not observed when the PB1 plasmid was omitted while omission of the PB2
plasmid had no impact on reporter activity (Fig 1C). Thus, the PB2 protein stably expressed in
293T cells was functional. Unfortunately, similar studies in MDCK cells were not feasible due
to the low transfectability of these cells.
PB2 expression allows production of infectious DI-244 in the absence of
standard virus
We next investigated whether the 293T-PB2 and MDCK-PB2 cells allowed the generation of
DI-244 particles, using the experimental setup depicted in Fig 2A. In order to be able to visually
inspect DI-244 production and spread, we generated a DI-244 variant that encodes for mScar-
let-i, a red fluorescent protein [26]. Transfection of a mixture of 293T/MDCK cells with plas-
mids encoding IAV wt segments 2–8 jointly with a plasmid encoding DI-244-mScarlet-i
resulted in occasional and moderate red fluorescence (Fig 3A). In contrast, frequent and promi-
nent red fluorescence was observed in 293T-PB2/MDCK-PB2 cocultures (Fig 3A), indicating
that the stably expressed PB2 promoted amplification of the DI-244-mScarlet-i DI RNA.
In order to examine whether amplification of the DI-244-mScarlet-i DI RNA resulted in
the production of infectious DIPs, the supernatants of the transfected 293T-PB2/MDCK-PB2
cells were inoculated onto MDCK-PB2 cells (Fig 2B). As controls, the supernatants were also
added to MDCK wt cells. Inoculation of MDCK-PB2 cells with supernatants from 293T-PB2/
MDCK-PB2 cells resulted in infection of the target cells, as determined by expression of
mScarlet-i (Fig 3B). The number of mScarlet-i-positive cells was concentration dependent and
supernatants taken at 6 days post transfection from DIP producing cells contained the highest
amount of infectivity (Fig 3B). Finally, no cells with prominent red fluorescence were detected
under control conditions, indicating that DIPs were only infectious for MDCK-PB2 but not
MDCK wt cells.
We next asked whether DI-244 production could be quantified by focus formation assay,
which is based on detection of IAV antigens by antibody staining and is frequently employed
to measure IAV infectivity. Moreover, we examined whether results obtained in the focus for-
mation assay would match those obtained upon counting of foci based upon red fluorescence.
Foci were observed in MDCK-PB2 but not in MDCK control cells, confirming that DIP infec-
tivity requires PB2 expression in target cells. Quantification of DIP infectivity by focus forma-
tion assay revealed that maximum titers of roughly 1 x 103 DIPs per ml were obtained and
counting red fluorescent foci yielded roughly comparable results (Fig 3B and Fig 3C). Thus,
expression of PB2 is sufficient for DI-244 production in the absence of helper virus but pro-
duction efficiency is moderate.
Codon optimization of PB2 allows increased PB2 expression and DIP
production
DIP titers of 1 x 103 particles per ml are low and may limit experimentation. Therefore, we
next asked whether alteration of codon usage for PB2 expression might increase PB2
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expression efficiency and DIP production. For this, we modified the codons in the PB2 expres-
sion plasmid (S1 Fig) to reflect codon preferences of human genes and IAV. As a second crite-
rion for codon choice, we opted for maximal sequence difference between the A/PR/8/
34-based sequence previously used for PB2 expression and the newly generated, optimized
PB2 sequence (PB2opt), in order to prevent potential recombination events. 293T and MDCK
cells were engineered to stably express PB2opt and immunoblot revealed that expression levels
of PB2opt in MDCK but not 293T cells were higher than those obtained upon expression of
non-codon-optimized PB2 (Fig 1A and Fig 1B). Moreover, growth of PB2opt cells was compa-
rable to that of control cells and PB2opt expression was readily detectable after multiple pas-
sages, suggesting that expression was not associated with overt cytotoxicity. Finally, analysis of
Fig 1. Stable expression of active PB2 protein in 293T and MDCK cells. (A) 293T and MDCK cells engineered to stably express PB2 or codon-
optimized PB2 (PB2opt) were analyzed for PB2 expression by immunoblot using anti-PB2 antibody. Detection of beta-actin expression served as
loading control. Similar results were obtained in four separate experiments. (B) The average of five experiments conducted as described for panel A
and quantified via the ImageJ program is shown. Signals measured for PB2 or PB2opt were normalized against those measured for beta-actin. Error
bars indicate standard error of the mean (SEM). Two tailed paired students t-test was used to assess statistical significance. (C) 293T cells stably
expressing PB2 were cotransfected with plasmids encoding an IAV luciferase reporter segment and the indicated IAV proteins. Luciferase activities in
cell lysates were determined at 24 h post transfection. The results of a representative experiment carried out with triplicate samples are shown. Error
bars indicate standard deviation. Two tailed paired students t-test was used to assess statistical significance. Similar results were obtained in three
separate experiments. C.p.s., counts per second.
https://doi.org/10.1371/journal.pone.0212757.g001
New system for production of defective interfering particles
PLOS ONE | https://doi.org/10.1371/journal.pone.0212757 March 1, 2019 7 / 18
New system for production of defective interfering particles
PLOS ONE | https://doi.org/10.1371/journal.pone.0212757 March 1, 2019 8 / 18
293T-PB2opt cells in the mini-replicon assay showed that PB2opt supported IAV segment rep-
lication (Fig 4).
Next, we examined whether PB2opt supports DIP production with higher efficiency than
unmodified PB2. Efficient DI-244-mScarlet-i DI RNA amplification was observed in trans-
fected PB2opt cells (not shown) and supernatants obtained from these cells were highly infec-
tious for MDCK-PB2opt cells even when diluted 1:1,000 (Fig 5A). In contrast, the
supernatants were not infectious for MDCK cells (Fig 5A). Moreover, a direct comparison of
293T-PB2/MDCK-PB2 and 293T-PB2opt/MDCK-PB2opt cells for production of infectious
DIPs and for DIP amplification upon infection revealed that the PB2opt cells were more effi-
cient. Thus, more red fluorescent cells were observed when supernatants from PB2 expressing
cells were added to MDCK-PB2opt as compared to MDCK-PB2 cells (Fig 5B). Similarly,
supernatants from PB2opt cells were more infectious for target MDCK-PB2opt cells as com-
pared to MDCK-PB2 cells. In keeping with this observation, quantification of production of
infectious DIPs by focus formation assay and counting of red fluorescent cells revealed that at
least 80% of foci (identified by antibody staining) were positive for mScarlet-i, as expected, and
that PB2opt cells produced up to 4 x 106 infectious DIPs per ml and thereby exceeded titers
obtained with PB2 cells (2,5 x 103) by ~1,500-fold (Fig 5C and Fig 5D).
DI-244 produced in the absence of standard virus exerts antiviral activity
DI-244 can inhibit spread of diverse IAVs and, likely via induction of interferon (IFN), may
also inhibit spread of unrelated viruses [3, 4]. In order to investigate the antiviral activity of
DI-244-mScarlet-i, we first analyzed whether DI-244-mScarlet-i produced in PB2opt cells
interfered with the spread of a homologous IAV, A/PR/8/34, in MDCK cells (Fig 2C). For this,
MDCK cells were coinfected with the indicated dilutions of DI-244 containing supernatants
and A/PR/8/34 at an MOI of 0.1, 0.01 and 0.001 (Fig 6A). This resulted in IAV/DIP ratios of
approximately 1:10 (undiluted DIP containing supernatants, IAV at MOI 0.1), 1:100 (undi-
luted DIP containing supernatants, IAV at MOI 0.01) and 1:1,000 (undiluted DIP containing
supernatants, IAV at MOI 0.001), respectively. The supernatants from 293T/MDCK wt cells
transfected with plasmids for DI-244 production were used as negative control. The control
supernatants did not appreciably interfere with A/PR/8/34 infection while supernatants from
PB2opt cells efficiently blocked IAV infection in a concentration dependent manner, with
highest antiviral activity observed at an IAV/DIP ratio of 1:1,000 (Fig 6A). Specifically, infec-
tion efficiency relative to untreated virus (set as 100%) was 1 ± 0.5% in the presence of DIP
containing supernatants at a dilution of 100 and 93 ± 13% in the presence of control superna-
tants (average of six independent experiments). Moreover, DI-244 containing supernatants
also inhibited infection by A/Panama/2007/99 (H3N2) in a concentration dependent manner
(Fig 6B), in keeping with the concept that DI-244 exerts broad anti-IAV activity [3, 4]. Finally,
DI-244 containing supernatants did not inhibit VSV infection (Fig 6C), indicating that DI-244
neither interfered with VSV genome replication nor altered viral control by a potential IFN
response in MDCK cells. These results show that DI-244 produced in PB2opt expressing cells
exerts potent anti-IAV activity.
Fig 2. Schematic representation of the work-flow employed for DIP production and characterization. (A) For
production of DIPs (DI-244-mScarlet-i), a coculture of 293T-PB2 and MDCK-PB2 cells was cotransfected with
plasmids harboring DI-244-mScarlet-i and the wt IAV genomic segments two to eight. Subsequently, trypsin was
added for HA activation and supernatants were harvested at the indicated time points. (B) For quantification of DIP
production, MDCK-PB2 cells were inoculated with DIP containing supernatants and the number of red cells was
counted or the number of foci was determined using focus formation assay. (C) For analysis of antiviral activity of
DIPs, MDCK cells were coinfected with IAV wt and DIPs followed by focus formation assay.
https://doi.org/10.1371/journal.pone.0212757.g002
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Fig 3. Production of DI-244 particles in PB2 expressing cell lines. (A) Cocultures of 293T-PB2/MDCK-PB2 cells were transfected with
plasmids encoding wt IAV segments 2–8 and DI-244-mScarlet-i. The presence of red fluorescence at 4, 6, 8 and 10 days post transfection
was analyzed using confocal microscopy. (B) MDCK control and MDCK-PB2 cells were infected with serially diluted DI-244 containing
supernatants harvested at the indicated time points and produced as described in panel A followed by removal of supernatants and
addition of methyl cellulose overlay. Thereafter, the presence of red fluorescent cells was analyzed at 72 h post infection using confocal
New system for production of defective interfering particles
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Discussion
The generation of DIPs in IAV infected cells has been recognized by von Magnus several
decades ago [33] and DIPs hold promise as novel antiviral agents [3, 4]. However, exploitation
of DIPs for antiviral therapy requires efficient production systems that do not depend on the
presence of standard virus. Here, we report a DI-244 variant encoding a fluorescent protein
that permits monitoring of DIP production. Moreover, we demonstrate that cells expressing
microscopy. (C) The number of infected cells (as determined by red fluorescence) in panel B was quantified. In parallel, infection of cells
was analyzed by focus formation assay and the number of foci quantified. The results of a representative experiment are shown in panels
A-C and were confirmed in two separate experiments.
https://doi.org/10.1371/journal.pone.0212757.g003
Fig 4. PB2opt stably expressed in 293T cells is active. 293T cells stably expressing PB2opt were cotransfected with plasmids encoding an IAV luciferase
reporter segment and the indicated IAV proteins. Luciferase activities in cell lysates were determined at 24 h post transfection. The results of a representative
experiment carried out with triplicate samples are shown. Error bars indicate standard deviation. Similar results were obtained in three separate experiments.
Two tailed paired students t-test was used to assess statistical significance. C.p.s., counts per second.
https://doi.org/10.1371/journal.pone.0212757.g004
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PB2 allow generation of infectious DI-244 particles solely from plasmids and in the absence of
standard virus. Finally, our study shows that DIPs produced in this system suppress spread of
different IAV subtypes but not VSV in cell culture.
DI-244 particles and other DIPs have so far been amplified in cell culture or hen’s eggs in
the presence of standard virus [3, 4, 17]. In addition, production of DI-244 particles from a
plasmid system has been described [34, 35]. This approach relies on the transfection of plas-
mids for production of infectious IAV in conjunction with a plasmid containing the DI-244
segment and results in the co-production of DIPs and standard virus [34, 35]. Before DIP
preparations produced in these systems can be used for experimentation, the remaining stan-
dard virus needs to be inactivated by UV light [18]. This approach builds on the preferential
inactivation of standard virus relative to DIPs. Thus, a mutation in a gene essential for viral
spread will abrogate infectivity of standard virus but may have no effect on DIP infectivity
since the missing proteins will be complemented in trans in cells coinfected with DIPs and
standard virus. However, controlling the efficiency of UV inactivation of standard virus is
technically challenging. Moreover, the effect of UV light on DIP infectivity is difficult to deter-
mine and both issues may complicate large scale production of DIPs as well as interpretation
of experimental data and animal trials. Thus, establishment of novel cell culture systems for
DIP production in the absence of standard virus is an important task.
Our results show that cell lines expressing PB2 allow production and quantification of DI-
244 particles solely from plasmids and in the absence of standard virus. This finding was not
expected given that several reports indicate that PB2 expression alone is insufficient to allow
robust spread of IAV variants with temperature sensitive mutations in the PB2 gene at non-
permissive temperatures [20, 21]. Moreover, it has been suggested that PB2 expression might
be associated with unwanted cytotoxic effects [4]. The present study suggests that up to 4 x 106
DI-244 particles/ml can be produced in cells expressing codon optimized PB2, which roughly
translates into production of 10 infectious DIPs per cell, and it can be speculated that efficiency
of DIP production can be further increased by employing cell lines stably coexpressing PB1,
PB2 and PA. Occasionally, weak fluorescence has been observed in DIP inoculated control
cells. This is most likely attributable to low levels of DI-244 mRNA expression facilitated by
PB2 protein associated with DI-244 vRNA present in the infecting DIPs. In contrast, no evi-
dence for production of infectious IAV due to recombination between the DI-244 RNA and
the RNA encoding for PB2 was obtained, as judged by bright field microscopy, immunofluo-
rescence, focus formation assay and RT-PCR analysis, indicating that the DIP production sys-
tem reported here is safe.
Quantification of DIP production so far relied on quantitative RT-PCR and hemagglutina-
tion assay [4, 8, 17], which do not provide information on particle infectivity. This limitation
has been overcome by the present study which demonstrates that infectivity of DI-244 particles
can be quantified using a standard technique, focus formation assay. The availability of this
Fig 5. Codon optimization of PB2 results in increased DIP production. (A) DI-244 containing supernatants were produced in
293T-PB2opt/MDCK-PB2opt cells and harvested at the indicated time points as described for panel A of Fig 2. Subsequently, MDCK
control and MDCK-PB2opt cells were infected with serially diluted DI-244 containing supernatants followed by removal of supernatants
and addition of methyl cellulose overlay. Thereafter, the presence of red fluorescent cells was analyzed at 72 h post infection using confocal
microscopy. (B) DI-244 supernatants produced in cells expressing PB2 or PB2opt were inoculated onto the indicated MDCK target cells as
described for panel B and the presence of red fluorescent cells was analyzed at 72 h post infection using confocal microscopy. (C) The
number of infected cells (as determined by red fluorescence) in panel A was quantified. In parallel, infection of cells was analyzed by focus
formation assay and the number of foci was quantified. The results of a representative experiment are shown in panels A-C and were
confirmed in two separate experiments. (D) The average of three (PB2) and six (PB2opt) independent experiments conducted as described
for panel A is shown. Supernatants obtained at six days post transfection were analyzed, infection of cells was quantified by focus formation
assay. Error bars indicate SEM.
https://doi.org/10.1371/journal.pone.0212757.g005
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method should help comparing results obtained with different DI-244 preparations or other
segment 1 DIPs and should thus advance the development of DIPs as antiviral agents. In this
context, it is noteworthy that a IAV/DIP ratio of 1:1,000 resulted in the most prominent antivi-
ral activity in our hands and a very similar ratio, 1:3,400 (as determined by estimations based
on quantitative RT-PCR (DIP) and infectious units (IAV)), was previously reported to be
Fig 6. DI-244 produced in PB2opt expressing cell lines exerts anti-IAV activity. (A) Undiluted or 10-fold serially diluted DIP supernatants harvested from
transfected 293T-PB2opt/MDCK-PB2opt cells or supernatants from transfected 293T/MDCK control cells were co-inoculated with A/PR/8/34 (H1N1) onto MDCK
cells. Fresh medium was added at 1 h post infection and infectivity present in supernatants harvested at 72 h post infection was analyzed by focus formation assay.
The average of three (MOI 0.1, MOI 0.01) and six (MOI 0.001), respectively, independent experiments is shown. Infection in the absence of supernatants was set as
100%. Error bars indicate standard error of the mean (SEM). Two tailed paired students t-test was used to assess statistical significance. (B) The experiment was
carried out as described for panel A but A/Panama/2007/99 (H3N2) was used for infection. The average of three independent experiments is shown. Infection in the
absence of supernatants was set as 100%. Error bars indicate SEM. Two tailed paired students t-test was used to assess statistical significance. (C) The experiment was
carried out as for panel A but cells were infected with GFP-encoding VSV and supernatants were harvested for titration at 24 h post infection. The results of a single
representative experiment conducted with triplicate samples are shown and were confirmed in two separate experiments.
https://doi.org/10.1371/journal.pone.0212757.g006
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minimally required to protect mice from severe influenza [4]. Thus, our study confirms and
extends published work indicating that DIPs have to be provided in vast excess to exert antivi-
ral activity. Whether sufficient numbers of DIPs can be delivered to the human respiratory
tract and remain stable to provide protection against influenza for a prolonged time remains
to be determined. In this context, one can speculate that an IAV:DIP ratio of less than 1:1,000
might be sufficient for antiviral activity in humans, since DIPs might exert direct antiviral
activity by inhibiting IAV genome replication and induce the IFN system. Moreover, DIPs
were reported to have a long residence time in the respiratory tract of mice and DIP-treated
animals were found to still be protected at one week after treatment [4, 35]. Thus, DIP stability
in the respiratory tract might not pose a major hurdle to the use of DIPs for influenza preven-
tion and therapy in humans. Finally, it should be stated that reassortment of DIPs with IAV in
coinfected cells is likely to occur. However, if DIPs based on the low pathogenic A/PR/8/34 or
related viruses are used (like in the present study), such reassortment events should not result
in viruses with increased transmissibility or virulence as compared to the wt virus.
It is believed that DI-244 can interfere with spread of diverse IAV in cell culture due to
genome competition [3, 4]. Indeed, DI-244 produced in PB2opt cells exerted comparable anti-
viral activity against H1N1 and H3N2 IAV (no statistically significant differences), in keeping
with H3N2 polymerase complexes being fully functional on H1N1 genomic segments [36].
This matches data published for DI-244 generated by use of standard virus [35] and demon-
strates that DIPs produced in PB2 expressing cells are fully functional, although the activity of
purified DIPs remains to be examined. DI-244 can also interfere with the spread of influenza B
virus (IBV) and unrelated respiratory viruses in the infected host and this is thought to be due
to induction of innate immune responses, particularly the IFN response [14, 16]. In contrast,
DIP-mediated inhibition of IBV infection in cell culture is not observed, due to absence of
genome competition [13, 14]. The absence of antiviral activity of DIPs against VSV confirms
lack of genome competition. Moreover, it suggests that DIPs might not have modulated a
potential IFN response in MDCK cells, although it should be noted that such a response might
have been impeded due to the presence of trypsin in the culture medium [37].
Collectively, we report, to our knowledge, the first experimental system for production of
DIPs without standard virus and for quantification of DIP infectivity, which should promote
efforts to develop DIPs for antiviral therapy.
Supporting information
S1 Fig. Alignment of PB2 and codon optimized PB2. The nucleotide sequences of PB2-wt
(PB2) and codon optimized PB2 (PB2opt) were aligned using the Clustal W algorithm of
AlignX (Vector NTI). Divergent nucleotides are marked in black.
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